0001104659-26-014708
SEC filingCVRx, Inc. reported revenue of $56.7 million for fiscal year 2025, generating a gross profit of $48.3 million. The company incurred a net loss of $53.3 million, with a loss from operations of $51.3 million, driven by total operating expenses of $99.6 million, primarily from selling, general and administrative expenses of $88.5 million. The company's cash position decreased by $30.2 million to $90.6 million, with net cash used in operating activities of $40.2 million partially offset by net cash provided by financing activities of $10.5 million. Total assets stood at $104.8 million, with total liabilities of $65.5 million and stockholders' equity of $39.3 million. The company's accumulated deficit increased to $590.7 million, reflecting continued investment in operations despite revenue growth.
CVRx, Inc. reported revenue of $56.7 million for fiscal year 2025, with cost of goods sold of $8.3 million resulting in gross profit of $48.3 million. The company incurred significant operating expenses totaling $99.6 million, comprising $11.1 million in research and development and $88.5 million in selling, general and administrative expenses. This resulted in a loss from operations of $51.3 million. After accounting for interest expense of $5.8 million and other income of $3.8 million, the company reported a loss before income taxes of $53.3 million. With a minimal income tax provision of $18,000, the net loss was $53.3 million, consistent with comprehensive loss after including a cumulative translation adjustment of $2,000. Basic and diluted net loss per share was $2.00, calculated using weighted-average common shares of 26.1 million.
The company reported total revenue of $56.7 million for fiscal year 2025. No segment breakdown, geographic mix, or specific growth drivers were disclosed in the provided financial data. The revenue figure represents the company's total sales for the period without further categorization or comparative analysis against prior periods in the available data.
The company achieved a gross margin of 85.2% based on revenue of $56.7 million and gross profit of $48.3 million. Operating margin was negative 90.5% due to the loss from operations of $51.3 million relative to revenue. The cost structure shows operating expenses significantly exceeding gross profit, with selling, general and administrative expenses representing the largest component at $88.5 million, followed by research and development expenses of $11.1 million. No comparative margin data from prior periods was provided in the available financial information.
Net cash used in operating activities was $40.2 million, primarily driven by the net loss of $53.3 million, adjusted for non-cash items including stock-based compensation of $11.1 million and depreciation of $756,000. Investing activities used $580,000 for property and equipment purchases. Financing activities provided $10.5 million from equity issuances, including $9.0 million from common stock issuance and $1.5 million from stock options and employee stock purchases. The net change in cash was a decrease of $30.2 million, resulting in cash and cash equivalents of $90.6 million at year-end. Total assets were $104.8 million, including current assets of $101.6 million. Total liabilities were $65.5 million, with long-term debt of $49.5 million. Stockholders' equity was $39.3 million, with accumulated deficit of $590.7 million.
No management guidance, strategic priorities, or specific risk factors were disclosed in the provided financial data. The filing contains standard financial statements without forward-looking statements or outlook commentary in the extracted content. Investors should refer to the complete 10-K filing for comprehensive risk factor disclosure and management discussion and analysis sections that typically contain forward-looking information.